{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:07:48Z","timestamp":1776283668871,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0173507","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T13:54:40Z","timestamp":1488808480000},"page":"e0173507","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor"],"prefix":"10.1371","volume":"12","author":[{"given":"Brian J.","family":"North","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Almeciga-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tamang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon S.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven N.","family":"Quayle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/ehm.12.62","article-title":"Immunomodulatory drugs in multiple myeloma","volume":"6","author":"S Andhavarapu","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2013.03.016","article-title":"Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy","volume":"13","author":"JL Kaufman","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11899-016-0312-7","article-title":"Practical Approaches to the Management of Dual Refractory Multiple Myeloma","volume":"11","author":"HC Lee","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"5971","key":"ref4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"T Ito","year":"2010","journal-title":"Science"},{"issue":"6168","key":"ref5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"J Kronke","year":"2014","journal-title":"Science"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"A Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"6168","key":"ref7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"G Lu","year":"2014","journal-title":"Science"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"AK Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"CC Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","article-title":"Addiction to c-MYC in multiple myeloma","volume":"120","author":"T Holien","year":"2012","journal-title":"Blood"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"A Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"issue":"7201","key":"ref12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"AL Shaffer","year":"2008","journal-title":"Nature"},{"issue":"1\u20132","key":"ref13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"HP Chen","year":"2015","journal-title":"Crit Rev Oncog"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0609.2009.01384.x","article-title":"Vorinostat enhances the antimyeloma effects of melphalan and bortezomib","volume":"84","author":"RA Campbell","year":"2010","journal-title":"Eur J Haematol"},{"issue":"10","key":"ref15","article-title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy","volume":"6","author":"Y Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1073\/pnas.2536759100","article-title":"Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications","volume":"101","author":"CS Mitsiades","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical Toxicities of Histone Deacetylase Inhibitors","volume":"3","author":"S Subramanian","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref18","article-title":"Histone deacetylases function as novel potential therapeutic targets for cancer","author":"H Zhang","year":"2016","journal-title":"Hepatol Res"},{"issue":"8","key":"ref19","doi-asserted-by":"crossref","first-page":"e0136193","DOI":"10.1371\/journal.pone.0136193","article-title":"Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT\/mTOR Signaling","volume":"10","author":"P Zhang","year":"2015","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1038\/bcj.2015.38","article-title":"Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma","volume":"5","author":"T Hideshima","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2015.03.016","article-title":"Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma","volume":"364","author":"DY Shin","year":"2015","journal-title":"Cancer Lett"},{"issue":"31","key":"ref22","doi-asserted-by":"crossref","first-page":"31134","DOI":"10.18632\/oncotarget.5290","article-title":"HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide","volume":"6","author":"A Canella","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"JE Bradner","year":"2010","journal-title":"Nat Chem Biol"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12185-016-2008-0","article-title":"Histone deacetylase inhibitors in multiple myeloma: from bench to bedside","volume":"104","author":"T Harada","year":"2016","journal-title":"Int J Hematol"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/epi.10.59","article-title":"Histone deacetylase inhibitors in the therapy of cancer: much to learn","volume":"2","author":"JH Lee","year":"2010","journal-title":"Epigenomics"},{"issue":"2","key":"ref26","first-page":"180","article-title":"HDAC inhibitors in cancer care","volume":"24","author":"JE Shabason","year":"2010","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"AC West","year":"2014","journal-title":"J Clin Invest"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"AJ Yee","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.18632\/oncotarget.13738","article-title":"Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models","volume":"8","author":"P Huang","year":"2017","journal-title":"Oncotarget"},{"issue":"6887","key":"ref30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"C Hubbert","year":"2002","journal-title":"Nature"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"E Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"L Santo","year":"2012","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"TC Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"H Garg","year":"2016","journal-title":"Cancer Cell Int"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/sj.leu.2404602","article-title":"Significant impact of survivin on myeloma cell growth","volume":"21","author":"M Romagnoli","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbrc.2004.09.130","article-title":"Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1\/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells","volume":"324","author":"H Li","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"ref37","first-page":"169","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines","volume":"15","author":"Y Xu","year":"2005","journal-title":"Int J Mol Med"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12020-015-0706-7","article-title":"The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells","volume":"51","author":"SH Kim","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","article-title":"Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels","volume":"16","author":"D Mahalingam","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"25","key":"ref40","doi-asserted-by":"crossref","first-page":"37693","DOI":"10.18632\/oncotarget.9264","article-title":"MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer","volume":"7","author":"S Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbagen.2011.11.011","article-title":"Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells","volume":"1820","author":"YF Hsu","year":"2012","journal-title":"Biochim Biophys Acta"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0173507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T06:20:19Z","timestamp":1568874019000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0173507"}},"subtitle":[],"editor":[{"given":"Javier S","family":"Castresana","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,6]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0173507","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,6]]}}}